FDA approves anthrax treatment Anthrasil
The treatment is an Anthrax Immune Globulin Intravenous (AIGIV) solution that consists of polyclonal antibodies that target the damaging portions and toxic material in the bacteria. The antibodies come from donors who have been vaccinated with the company's anthrax vaccine, BioThrax.
FDA approval grants the company seven years of product exclusivity, and the company receives $7 million from its contract with the Biomedical Advanced Research and Development Authority (BARDA).
"Anthrasil remains an integral part of the U.S. government's strategic national stockpile, and we are committed to working collaboratively with BARDA and CDC to further advance this program," Adam Havey, president of the bio-defense division with Emergent, said.
The solution was developed through a $160 million contract, originally awarded in 2005, with BARDA for development of a treatment option. The company is also under a $63 million contract to collect anti-anthrax components from healthy human plasma.
Emergent is a bio-pharmaceutical company specializing in the development of treatment options and other health care-specific products and solutions for government and industry entities. One of its main focuses is addressing unmet treatment needs against emerging threats to human health.